Charles Theuer - 26 Apr 2023 Form 4 Insider Report for Tracon Pharmaceuticals, Inc.

Role: President and CEO, Director
Signature: /s/ Scott B. Brown, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 26 Apr 2023
Net transactions value: +$37,889
Form type: 4
Filing time: 28 Apr 2023, 06:00:11 UTC
Previous filing: 02 Mar 2023
Next filing: 25 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TCON	Common Stock	Purchase	$2,639	+3,999	+1.1%	$0.6600	352,417	26 Apr 2023	Direct	F1
transaction	TCON	Common Stock	Purchase	$35,250	+47,000	+13%	$0.7500	399,417	27 Apr 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 3,500 shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on April 20, 2023.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.72 to $0.7596, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Content

Includes 3,500 shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on April 20, 2023.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.72 to $0.7596, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.